Next Week's Earnings Focus on Netflix, 3M, and More
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 17 2026
0mins
Should l Buy JNJ?
Source: CNBC
- Earnings Week Outlook: Next week will feature earnings reports from Netflix, 3M, and D.R. Horton, with Cramer noting that despite disappointing results from homebuilders, he is starting to see 'green shoots' in the housing market, indicating potential recovery signs.
- 3M Surprises: Cramer highlights that 3M has been quietly surprising investors this year, and he expects its earnings report to continue delivering positive surprises, reflecting the company's success in diversifying its business.
- Johnson & Johnson's Strategic Shift: Cramer praises Johnson & Johnson's move towards becoming primarily a pharmaceutical company, suggesting that while it faces lawsuits related to talc products, these issues have limited impact on its stock price, demonstrating resilience in the market.
- Inflation Data Focus: The PCE price index will be released on Thursday, with Cramer anticipating a 'restrained set of numbers,' which could influence market expectations regarding inflation and subsequently affect investor decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 226.100
Low
190.00
Averages
218.50
High
240.00
Current: 226.100
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
JOHNSON & JOHNSON RECEIVES CE MARK APPROVAL FOR NEW ETHICON™ 4000 STAPLER
Product Announcement: Johnson & Johnson has announced the approval of its new Ethicon™ 4000 stapler.
Significance: The new stapler is expected to enhance surgical procedures and improve patient outcomes.
See More
Johnson & Johnson Shares Set to End Six-Day Losing Streak
- Stock Rebound: Johnson & Johnson (JNJ) shares rose 1.9% to $230.42 on Thursday, breaking a six-day losing streak, despite a cumulative loss of about 5% during that period, indicating market expectations for a short-term recovery.
- Year-to-Date Performance: So far this year, JNJ's stock has increased nearly 10%, significantly outperforming the S&P 500's 4% rise, although it has declined nearly 2% over the past month, reflecting mixed market sentiment regarding its long-term growth potential.
- Analyst Ratings: According to Seeking Alpha's Quant Rating, JNJ holds a score of 3.43 with a Hold rating, receiving an A+ for profitability prospects but a D- for growth factors, highlighting analysts' confidence in its earnings while expressing concerns about growth potential.
- Market Outlook: While Johnson & Johnson is not typically known for mega M&A deals, its diversified portfolio, particularly with double-digit growth in Innovative Medicines and strong performance in MedTech, positions it as “the cleanest growth story in healthcare,” laying a solid foundation for future growth.
See More
Investment Analysis of Small vs. Large Healthcare Stocks
- Small-Cap Potential: CytomX Therapeutics, a clinical-stage company with a market cap of around $1 billion, focuses on cancer treatments and has seen its stock price skyrocket over 625% in the past year; however, it faces risks with no approved drugs and a reported net loss exceeding $20 million in 2025, highlighting the volatility of investing in smaller firms.
- Market Risks: Despite the significant price increase over the past year, CytomX's stock has dropped roughly 40% over the last five years, indicating that investors holding the stock for over four years may be facing losses, which underscores the inherent risks of small-cap healthcare investments.
- Large-Cap Stability: Johnson & Johnson, with a towering market cap of about $545 billion, achieved sales of $88.8 billion in 2024, with projections to grow to between $99.5 billion and $100.5 billion in 2026, showcasing its stable revenue streams and strong market position.
- Consistent Dividends: Johnson & Johnson not only provides stable income but has also increased its dividend for 64 consecutive years; while its sales growth may not match that of small-cap stocks, its stability and profitability make it an ideal choice for investors seeking stability and income.
See More
Investment Comparison: Small vs. Large Healthcare Stocks
- Small-Cap Potential: CytomX Therapeutics, a clinical-stage company with a market cap of around $1 billion, focuses on cancer treatments and has seen its stock price soar over 625% in the past year; however, with no approved drugs and a reported net loss of over $20 million in 2025, it exemplifies the high-risk, high-reward nature of small-cap investments.
- Investment Risks: While CytomX's stock has surged recently, it has dropped approximately 40% over the past five years, highlighting the volatility risks associated with early-stage companies, necessitating careful consideration of holding periods and potential losses by investors.
- Large-Cap Stability: Johnson & Johnson, with a market cap of about $545 billion, achieved sales of $88.8 billion in 2024, projected to rise to between $99.5 billion and $100.5 billion in 2026, showcasing a reliable revenue stream and the ability to consistently pay dividends, having increased its payout for 64 consecutive years.
- Investment Strategy Choice: Choosing between small-cap and large-cap stocks hinges on investors' goals and risk tolerance, with small-caps appealing to those seeking high returns and large-caps better suited for those prioritizing stability and income.
See More
Johnson & Johnson's Imaavy Shows Promising Phase 3 Results for Myasthenia Gravis
- Significant Clinical Improvements: In a study involving patients with generalized myasthenia gravis (gMG), Johnson & Johnson's Imaavy (nipocalimab) demonstrated sustained clinical improvements with average reductions of 6.47 points in MG-ADL and 5.97 points in QMG scores over a 120-week observation period, indicating its effectiveness in treating gMG.
- Reduced Symptom Expression: Approximately 50% of patients achieved minimal symptom expression, with about one-third maintaining this status for at least eight weeks, further highlighting Imaavy's potential to enhance patient quality of life.
- Substantial IgG Reduction: The study revealed a 64% reduction in total IgG levels, including pathogenic IgG autoantibodies considered underlying drivers of gMG, suggesting Imaavy's positive role in immune modulation.
- New Study Initiated: Johnson & Johnson has begun enrolling patients for a head-to-head study comparing Imaavy with argenx's Vyvgart (efgartigimod alfa), aiming to further validate Imaavy's efficacy and safety, potentially introducing new competitive dynamics in the market.
See More
EXCLUSIVE: SOURCES REVEAL MERCK AND COMPETITORS SHOWING INTEREST IN INHIBRX'S EXPERIMENTAL CANCER TREATMENT LINKED TO KEYTRUDA
Interest in InhibRx: Merck and other rivals are showing interest in InhibRx, a company involved in experimental cancer drug development.
Key Drug Tied to Trudeau: The experimental cancer drug being discussed is reportedly linked to key figures, including Canadian Prime Minister Justin Trudeau.
See More
JOHNSON & JOHNSON RECEIVES CE MARK APPROVAL FOR NEW ETHICON™ 4000 STAPLER
Product Announcement: Johnson & Johnson has announced the approval of its new Ethicon™ 4000 stapler.
Significance: The new stapler is expected to enhance surgical procedures and improve patient outcomes.
See More
Johnson & Johnson Shares Set to End Six-Day Losing Streak
- Stock Rebound: Johnson & Johnson (JNJ) shares rose 1.9% to $230.42 on Thursday, breaking a six-day losing streak, despite a cumulative loss of about 5% during that period, indicating market expectations for a short-term recovery.
- Year-to-Date Performance: So far this year, JNJ's stock has increased nearly 10%, significantly outperforming the S&P 500's 4% rise, although it has declined nearly 2% over the past month, reflecting mixed market sentiment regarding its long-term growth potential.
- Analyst Ratings: According to Seeking Alpha's Quant Rating, JNJ holds a score of 3.43 with a Hold rating, receiving an A+ for profitability prospects but a D- for growth factors, highlighting analysts' confidence in its earnings while expressing concerns about growth potential.
- Market Outlook: While Johnson & Johnson is not typically known for mega M&A deals, its diversified portfolio, particularly with double-digit growth in Innovative Medicines and strong performance in MedTech, positions it as “the cleanest growth story in healthcare,” laying a solid foundation for future growth.
See More
Investment Analysis of Small vs. Large Healthcare Stocks
- Small-Cap Potential: CytomX Therapeutics, a clinical-stage company with a market cap of around $1 billion, focuses on cancer treatments and has seen its stock price skyrocket over 625% in the past year; however, it faces risks with no approved drugs and a reported net loss exceeding $20 million in 2025, highlighting the volatility of investing in smaller firms.
- Market Risks: Despite the significant price increase over the past year, CytomX's stock has dropped roughly 40% over the last five years, indicating that investors holding the stock for over four years may be facing losses, which underscores the inherent risks of small-cap healthcare investments.
- Large-Cap Stability: Johnson & Johnson, with a towering market cap of about $545 billion, achieved sales of $88.8 billion in 2024, with projections to grow to between $99.5 billion and $100.5 billion in 2026, showcasing its stable revenue streams and strong market position.
- Consistent Dividends: Johnson & Johnson not only provides stable income but has also increased its dividend for 64 consecutive years; while its sales growth may not match that of small-cap stocks, its stability and profitability make it an ideal choice for investors seeking stability and income.
See More
Investment Comparison: Small vs. Large Healthcare Stocks
- Small-Cap Potential: CytomX Therapeutics, a clinical-stage company with a market cap of around $1 billion, focuses on cancer treatments and has seen its stock price soar over 625% in the past year; however, with no approved drugs and a reported net loss of over $20 million in 2025, it exemplifies the high-risk, high-reward nature of small-cap investments.
- Investment Risks: While CytomX's stock has surged recently, it has dropped approximately 40% over the past five years, highlighting the volatility risks associated with early-stage companies, necessitating careful consideration of holding periods and potential losses by investors.
- Large-Cap Stability: Johnson & Johnson, with a market cap of about $545 billion, achieved sales of $88.8 billion in 2024, projected to rise to between $99.5 billion and $100.5 billion in 2026, showcasing a reliable revenue stream and the ability to consistently pay dividends, having increased its payout for 64 consecutive years.
- Investment Strategy Choice: Choosing between small-cap and large-cap stocks hinges on investors' goals and risk tolerance, with small-caps appealing to those seeking high returns and large-caps better suited for those prioritizing stability and income.
See More
Johnson & Johnson's Imaavy Shows Promising Phase 3 Results for Myasthenia Gravis
- Significant Clinical Improvements: In a study involving patients with generalized myasthenia gravis (gMG), Johnson & Johnson's Imaavy (nipocalimab) demonstrated sustained clinical improvements with average reductions of 6.47 points in MG-ADL and 5.97 points in QMG scores over a 120-week observation period, indicating its effectiveness in treating gMG.
- Reduced Symptom Expression: Approximately 50% of patients achieved minimal symptom expression, with about one-third maintaining this status for at least eight weeks, further highlighting Imaavy's potential to enhance patient quality of life.
- Substantial IgG Reduction: The study revealed a 64% reduction in total IgG levels, including pathogenic IgG autoantibodies considered underlying drivers of gMG, suggesting Imaavy's positive role in immune modulation.
- New Study Initiated: Johnson & Johnson has begun enrolling patients for a head-to-head study comparing Imaavy with argenx's Vyvgart (efgartigimod alfa), aiming to further validate Imaavy's efficacy and safety, potentially introducing new competitive dynamics in the market.
See More
EXCLUSIVE: SOURCES REVEAL MERCK AND COMPETITORS SHOWING INTEREST IN INHIBRX'S EXPERIMENTAL CANCER TREATMENT LINKED TO KEYTRUDA
Interest in InhibRx: Merck and other rivals are showing interest in InhibRx, a company involved in experimental cancer drug development.
Key Drug Tied to Trudeau: The experimental cancer drug being discussed is reportedly linked to key figures, including Canadian Prime Minister Justin Trudeau.
See More
